Leucovorin CalciumDerivative of folic acid CAS# 6035-45-6 |
- Levomefolate calcium
Catalog No.:BCC1702
CAS No.:151533-22-1
Quality Control & MSDS
Chemical structure
3D structure
Number of papers citing our products
| Cas No. | 6035-45-6 | SDF | Download SDF |
| PubChem ID | 6335501 | Appearance | Powder |
| Formula | C21H25CaN7O7.5H2O | M.Wt | 617.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Leucovorin calcium salt pentahydrate | ||
| Solubility | H2O : 10 mg/mL (16.57 mM; Need ultrasonic) DMSO : < 1 mg/mL (insoluble or slightly soluble) | ||
| Chemical Name | (2S)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;calcium;pentahydrate | ||
| SMILES | C1C(N(C2=C(N1)NC(=NC2=O)N)C=O)CNC3=CC=C(C=C3)C(=O)NC(CCC(=O)O)C(=O)O.O.O.O.O.O.[Ca] | ||
| Standard InChIKey | DZNHRKNLTYYMQA-ZIGBGYJWSA-N | ||
| Standard InChI | InChI=1S/C20H23N7O7.Ca.5H2O/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30;;;;;;/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32);;5*1H2/t12?,13-;;;;;;/m0....../s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Folinic Acid is a reduced folic acid, which is used in combination with other chemotherapy drugs.
Target: Folate analog
Approved: 2008
Folinic acid (calcium salt pentahydrate) is the calcium salt form of folinic acid, which is one of the forms of folate found naturally in foods. Folate deficiency is believed to be the most common vitamin deficiency in the world due to food processing, food selection, and intestinal disorders. Folinic acid in the body can be converted into any of the other active forms of folate.
Treatment with folinic acid calcium salt pentahydrate (CF) could cause improved development in the heart and vessels in MTX-treated embryos, which proved that MTX induced the malformations by inhibiting DHFR. The transcript levels of genes such as hand2, mef2a, mef2c, and flk-1 were reduced in MTX-treated embryos. Compared with the MTX-treated group, the transcript levels of hand2, mef2a, mef2c, and flk-1 were increased in the MTX + dhfr-gfp mRNA-injected group and in the MTX + CF group [1]. Folinic acid may also be useful in the treatment of acute methotrexate overdose. Different dosing protocols are used, but folinic acid should be re-dosed until the methotrexate level is less than 5 x 10-8 M [2]. References: | |||||
Leucovorin Calcium Dilution Calculator
Leucovorin Calcium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6192 mL | 8.0959 mL | 16.1917 mL | 32.3834 mL | 40.4793 mL |
| 5 mM | 0.3238 mL | 1.6192 mL | 3.2383 mL | 6.4767 mL | 8.0959 mL |
| 10 mM | 0.1619 mL | 0.8096 mL | 1.6192 mL | 3.2383 mL | 4.0479 mL |
| 50 mM | 0.0324 mL | 0.1619 mL | 0.3238 mL | 0.6477 mL | 0.8096 mL |
| 100 mM | 0.0162 mL | 0.081 mL | 0.1619 mL | 0.3238 mL | 0.4048 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Human lymphoid cell lines were studied for leucovorin requirements to protect from methotrexate (MTX)-induced growth suppression. Over a 72h continuous exposure leucovorin provided better protection to the cell lines LAZ-007 and RAJI than to the cell line
- 9-O-Feruloyllariciresinol
Catalog No.:BCN4112
CAS No.:60337-67-9
- LY2090314
Catalog No.:BCC1717
CAS No.:603288-22-8
- GSK-3 inhibitor 1
Catalog No.:BCC4126
CAS No.:603272-51-1
- Sulprostone
Catalog No.:BCC7547
CAS No.:60325-46-4
- 4-Methoxyphenyl beta-D-glucopyranoside
Catalog No.:BCN1403
CAS No.:6032-32-2
- NBI 35965 hydrochloride
Catalog No.:BCC7567
CAS No.:603151-83-3
- Geissoschizine methyl ether
Catalog No.:BCN7736
CAS No.:60314-89-8
- Odanacatib (MK-0822)
Catalog No.:BCC1197
CAS No.:603139-19-1
- Sulforhodamine 101
Catalog No.:BCC8019
CAS No.:60311-02-6
- Tamarixetin
Catalog No.:BCN4116
CAS No.:603-61-2
- Chrysosplenetin
Catalog No.:BCN4115
CAS No.:603-56-5
- Auriculasin
Catalog No.:BCN3970
CAS No.:60297-37-2
- 6,7,8-Trimethoxycoumarin
Catalog No.:BCN4113
CAS No.:6035-49-0
- Doronine
Catalog No.:BCN2106
CAS No.:60367-00-2
- 7,8-Benzoflavone
Catalog No.:BCN6538
CAS No.:604-59-1
- Narcissoside
Catalog No.:BCN1263
CAS No.:604-80-8
- Tombozine
Catalog No.:BCN4117
CAS No.:604-99-9
- Cucurbitacin A
Catalog No.:BCN2468
CAS No.:6040-19-3
- Neopetasitenine
Catalog No.:BCN2114
CAS No.:60409-51-0
- Cauloside F
Catalog No.:BCN3848
CAS No.:60451-47-0
- Cytisine Hydrochloride
Catalog No.:BCN8133
CAS No.:6047-01-4
- Pifithrin-β
Catalog No.:BCC5503
CAS No.:60477-34-1
- Serpentinic acid
Catalog No.:BCN4616
CAS No.:605-14-1
- 5,6-Dihydropyridin-2(1H)-one
Catalog No.:BCN4013
CAS No.:6052-73-9
Functional impairment in submandibular gland of rats induced by 5-fluorouracil and calcium leucovorin.[Pubmed:23798072]
Acta Odontol Latinoam. 2012;25(3):262-8.
One of the main clinical problems during chemotherapy is the occurrence of severe systemic toxicities, including those related to the stomatognathic system, which contribute to reducing the patient's quality of life. The most frequent oral complications are mucositis, dysgeusia, inflammation, gingival bleeding and decreased salivary flow or hyposalivation, a factor that predisposes to xerostomia, and other local complications that alter the homeostasis of the system. The purpose of this study was to evaluate the functional activity of salivary glands in Wistar rats subject to chemotherapy by measuring salivary flow, glycogen levels and glandular tissue response to autonomic nervous system agonists. Five experimental groups were used: 1) Control group fed "ad libitum"; 2) 5-fluorouracil (20 mg/kg body weight); 3) Calcium leucovorin (10 mg/kg body weight); 4) 5-fluorouracil + calcium leucovorin (20 and 10 mg/kg, respectively) by intraperitoneal injection for five consecutive days and 5) control with paired diet. Groups 1 and 5 did not receive drugs. Treatment with fluorouracil + leucovorin produced an increase in stimulated salivary flow and a higher response to increasing doses of beta agonists compared to other experimental groups. In both groups treated with cytostatic drugs, blocking of glycogen consumption at the end of the experimental period was observed. Our work suggests that salivary secretion may be affected by a dual mechanism: the first would be toxicity induced by 5-FU, which would cause depression of the process of glucose utilization. The second mechanism would affect the sympathetic autonomic reflex arc. In this instance, the synergistic action of 5-FU + LV would have a negative effect on the nerve activity with a reduction of salivary secretion. This would explain the hyposalivation, cited by several authors in patients undergoing the 5-FU + LV scheme in the treatment of colon carcinoma.
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.[Pubmed:22567742]
Acta Gastroenterol Belg. 2012 Mar;75(1):14-21.
BACKGROUND: Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU. It could maintain significant plasma concentration of 5, 10-meTHF during the whole 5-FU perfusion with the potential of increasing 5-FU cytotoxicity. We conducted a randomized phase II clinical trial on Leucovorin Calcium (LV/Ca) and LV/Na in metastatic colorectal cancer patients (mCRC). Main objectives were to assess efficacy and safety. PATIENTS AND METHODS: Fifty seven patients with mCRC and no previous chemotherapy for metastatic disease were randomized to receive LV/Na or LV/Ca with irinotecan or oxaliplatine combined with infusional 5-FU. LV/Na was defined as warranting further evaluation in phase III if true overall response rate (ORR) > 35% (alpha=5%, beta=10% in case of true ORR >55%, 51 evaluable patients planned/arm). RESULTS: Results for LV/Ca and LV/Na arm respectively were: observed ORR, 55% (significantly higher than 35%, p = 0.02) and 61% (p = 0.004). Median overall survival durations were 11.9 months and 22.9 months (p = 0.02) and PFS 8.0 vs. 11.5 months (ns). Grade 3 events were 64% and 46% (p = 0.28). CONCLUSION: Both LV/Na and LV/Ca disclosed an ORR > 35% with comparable safety.
Analysis of saliva samples from oncological patients treated with 5-fluorouracil and leucovorin calcium by scanning electron microscopy with energy dispersive system.[Pubmed:23647127]
J Oral Pathol Med. 2013 Nov;42(10):788-92.
This work presents a chemical and morphological analysis of samples of saliva taken from patients who were under treatment with intravenous chemotherapy with 5-fluorouracil and Leucovorin Calcium. Samples of saliva were extracted from fifteen patients during the three stages of the treatment: The initial stage (previous to the chemotherapy), the intermediate stage (during the chemotherapy), and the final stage (twenty-one days after finishing the treatment). An amount of 50 mul was collected in each visit. Chemical contrast images were taken by means of scanning electron microscopy, and X-ray characteristic spectra were obtained from all the studied samples by using an energy dispersive system from all the studied samples. Images that correspond to the intermediate stage showed important differences with respect to the initial and final stages. In addition, X-ray spectra provided information about the present elements in saliva and their relative abundance allowed us to determine variations in the chemical composition. The backscattered electron images and X-ray spectra from the intermediate stage showed clusters of crystals with fluorine content higher than those obtained in initial and final stages. This fact probably indicates the passage of metabolites of 5-fluorouracil and Leucovorin Calcium from the plasma to the oral cavity. This finding enhances the hypothesis proposed by other authors about the secondary effects of the drugs on the stomatognathic system such as oral mucositis, dysgeusia, and xerostomia with or without hyposalivation.
